GoodRx (NASDAQ:GDRX) Shares Gap Up to $7.20

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $7.20, but opened at $7.80. GoodRx shares last traded at $7.48, with a volume of 376,414 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GDRX shares. The Goldman Sachs Group increased their price objective on shares of GoodRx from $6.50 to $7.50 and gave the company a “neutral” rating in a research report on Friday, March 1st. UBS Group increased their price objective on shares of GoodRx from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, March 1st. Barclays increased their price objective on shares of GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Monday. JPMorgan Chase & Co. raised shares of GoodRx from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $7.00 to $10.00 in a research report on Friday, March 1st. Finally, Raymond James raised shares of GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research report on Thursday, May 16th. One analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, GoodRx currently has an average rating of “Moderate Buy” and a consensus target price of $9.11.

GoodRx Stock Up 1.9 %

The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -719.28, a PEG ratio of 2.47 and a beta of 1.37. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. The business’s 50 day moving average price is $6.96 and its 200 day moving average price is $6.51.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The firm had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. On average, equities analysts forecast that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Beacon Capital Management LLC purchased a new position in shares of GoodRx during the 1st quarter worth $28,000. Citigroup Inc. raised its holdings in shares of GoodRx by 301.7% during the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock worth $45,000 after acquiring an additional 6,006 shares during the period. Gerber LLC purchased a new position in shares of GoodRx during the 4th quarter worth $75,000. Schnieders Capital Management LLC purchased a new position in shares of GoodRx during the 1st quarter worth $93,000. Finally, Innealta Capital LLC purchased a new position in shares of GoodRx during the 4th quarter worth $91,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.